Literature DB >> 2582031

The induction and suppression of in vitro IgG anti-tetanus toxoid antibody synthesis by human lymphocytes stimulated with tetanus toxoid in the absence of in vivo booster immunizations.

L G Lum, N J Culbertson.   

Abstract

This report presents a new approach that by-passes booster immunizations with tetanus toxoid (TT) before in vitro studies of antibody (Ab) production. The methodology for optimal TT-induced synthesis of specific IgG anti-tetanus toxoid Ab (IgG anti-TT) by peripheral blood mononuclear cells (PBMC) from randomly selected TT immune individuals without recent booster immunizations is described. PBMC from most normal immune subjects could be repeatedly induced to produce in vitro IgG anti-TT; PBMC from subjects with high TT titers are not required for this new approach. This approach uses high cell concentrations in multiple replicate microcultures and TT washout to obtain optimal IgG anti-TT synthesis. Washed cultures produced more Ab than nonwashed cultures (p less than or equal to 0.005). The readdition of TT (2.5 to 250 ng/ml) to the culture media after washout of TT on day 4 suppressed specific Ab formation, whereas diphtheria toxoid added at comparable doses did not inhibit specific Ab formation. Suppression of antibody synthesis mediated by T cells could be induced by TT per se, and was not due to binding of synthesized Ab to TT in the latter 8 days of culture. In addition, suppression could not be induced in the first 4 days of culture by IgG anti-TT, IgG, or IgM. This approach permits the analysis of antigen-specific regulatory circuits in the steady and activated immune states, and the evaluation of in vivo and in vitro effects of biologic response modifiers on specific Ab production.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2582031

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients.

Authors:  L G Lum; M C Seigneuret; R Storb
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

2.  Absence of complement fixing antibodies against lipopolysaccharides from Escherichia coli in a subgroup of patients with Crohn's disease.

Authors:  M Zeitz; U Hope; B Wust; C Galanos; B Möller; T J Lawley; E O Riecken
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

3.  In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients.

Authors:  V Barnaba; M Levrero; G Ruberti; A van Dyke; A Perrone; A Musca; F Balsano
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

4.  IgG anti-tetanus toxoid antibody synthesis by human bone marrow. I. Two distinct populations of marrow B cells and functional differences between marrow and peripheral blood B cells.

Authors:  L G Lum; E Burns; M M Janson; P J Martin; B R Giddings; M C Seigneuret; J E Noges; S C Galoforo
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

5.  Anti-tetanus toxoid antibody production after mismatched T cell-depleted bone marrow transplantation.

Authors:  M Benkerrou; D W Wara; M Elder; Y Dror; A Merino; B W Colombe; M Garovoy; M J Cowan
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

6.  CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.

Authors:  Lawrence G Lum; Archana Thakur; Qin Liu; Abhinav Deol; Zaid Al-Kadhimi; Lois Ayash; Muneer H Abidi; Cassara Pray; Elyse N Tomaszewski; Patricia A Steele; Dana L Schalk; Hiroshi Yano; Alice Mitchell; Melissa Dufresne; Joseph P Uberti; Voravit Ratanatharathorn
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-22       Impact factor: 5.742

7.  Regulation of the immune response in Plasmodium falciparum malaria: IV. T cell dependent production of immunoglobulin and anti-P. falciparum antibodies in vitro.

Authors:  L Kabilan; M Troye-Blomberg; M E Patarroyo; A Björkman; P Perlmann
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

8.  A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells.

Authors:  Kristina Nalivaiko; Martin Hofmann; Karina Kober; Nadine Teichweyde; Peter H Krammer; Hans-Georg Rammensee; Ludger Grosse-Hovest; Gundram Jung
Journal:  Mol Ther       Date:  2015-11-19       Impact factor: 11.454

9.  Immune T cells can transfer and boost anti-breast cancer immunity.

Authors:  Archana Thakur; Ritesh Rathore; Sri Vidya Kondadasula; Joseph P Uberti; Voravit Ratanatharathorn; Lawrence G Lum
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.